Menlo Park, CA ; 03/19/2020
Amount Funded: $30 Million
Type: Series E
Lead Investor: D1 Capital Partners
Participating Investor(s): Not Listed
Company Description: Founded in 2011, Sight Sciences has developed, and is now commercial with intelligently designed and engineered products that target the underlying causes of the world’s most prevalent eye diseases. The company’s surgical glaucoma product portfolio features the OMNI® Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target of all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) with a single device and single corneal incision.
What funding will be used for: Continuing clinical, operational development and commercial expansion for its eye health products.
“We are thrilled to be closing a significant growth investment round with D1. D1 is truly a perfect fit for our company at this stage, combining the scale, market reach, investment talent and operational acumen of a large, premier asset manager with the flexible mandate and long-term investment horizon of a family office.”
-Jesse Selnick, CFO of Sight Sciences
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.